Chinese drugmaker CanSino Biologics began trial production of a vaccine using mRNA technology to target the new variant of COVID-19 that is behind the country’s current outbreak.
Chinese drugmaker CanSino Biologics began trial production of a vaccine using mRNA technology to target the new variant of COVID-19 that is behind the country’s current outbreak.